Medical device development company Evolve Medtech Partners announced on Wednesday that Rob Abrams has joined the company's team.
With more than 30 years of experience in biomedical device product development, research, operational management, new business development and strategic investments, Abrams currently serves as a senior global business development and strategy executive with Kaneka Corp.
Abrams previously served as an operating partner at Sanderling Ventures and CEO of Pulsar Vascular, which was acquired by Johnson & Johnson.
Before he joined Sanderling, Abrams was group vice president of new business development for cardiovascular at Boston Scientific and has also served in various roles at Target Therapeutics, Localmed, Howmedica, and Guidant. lve-medtech.com
Genentech reports positive Phase II results for enicepatide in type 2 diabetes
Otsuka ICU Medical recalls 0.9% Sodium Chloride Injection
US FDA grants orphan drug designation for Lundbeck's asedebart
Seismic Pharmaceuticals enrols first patient in istaroxime global Phase 3 trial in cardiogenic shock
Ionis partner Novartis reports pelacarsen Phase 3 trial misses primary endpoint
Thryv Therapeutics licenses new class of SGK1 inhibitors, expanding into neurodegenerative disease
Lilly to acquire Merida Biosciences in USD2.875bn deal
GE HealthCare expands Vivid cardiovascular ultrasound portfolio with three new systems
Daiichi Sankyo data highlight real-world impact of bempedoic acid on cardiovascular risk
Revier Therapeutics closes EUR6m seed financing and launches operations
Tempus announces receipt of FDA clearance for AI pulmonary hypertension detection product
European Commission grants orphan designation for Lundbeck's asedebart
Hanmi Pharm enters exclusive licensing deal with Genentech for obesity therapy HM17321
PTC to acquire BLA-stage ST-920 Fabry disease programme
Olio Labs reveals study demonstrating AI-driven in vivo platform can predict clinical trial outcomes